FDA greenlights first vaccine for RSV prevention in infants via active gestational immunization
The Food and Drug Administration announced its approval of Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease and severe LRTD caused by respiratory syncytial virus in infants from birth through six months of age. FDA says Abrysvo is approved for use at 32 through 36 weeks gestational age of pregnancy. The approval follows a clinical study that confirmed Abrysvo’s effectiveness to prevent LRTD and severe LRTD caused by RSV in infants born to individuals who were vaccinated during pregnancy.
Related News Articles
Headline
Health care organizations can create more inclusive, responsive and effective maternal health initiatives that address the unique challenges Black women…
Blog
Black women in the U.S. experience maternal mortality rates at nearly three times that of white women, regardless of income or education level. This…
Headline
Given the pressures of parenting, learn how health care organizations are supporting new moms to enable them to thrive at work, and most importantly, at home,…
Headline
Mounting pressures on the health care workforce have created a crisis with short-term staffing shortages and a long-range picture of an unfulfilled talent…
Headline
Cardiovascular conditions are one of the most common causes of morbidity and mortality among pregnant women. AHA’s Better Health for Mothers and Babies…
Headline
Kittitas Valley Healthcare in rural Washington state last year implemented an innovative new model for retaining essential obstetric and other women’s health…